July 12, 2016
Nektar Therapeutics Presents Abuse Potential Assessment of Novel Opioid Analgesic NKTR-181 at Arrowhead’s Upcoming 10th Annual Pain Summit
In the past several years, the FDA has been providing an incentive to develop abuse-deterrent products by offering differentiated labeling claims for products that meet the current required standards. Abuse potential, or the likelihood that a drug will be used for its positive psychoactive effects in nonmedical methods, was of crucial concern for Nektar Therapeutics when developing NKTR-181, a novel opioid analgesic.
NKTR-181 is a new molecule opioid candidate which is designed to have a reduced rate and extent of entry into the CNS, which in turn reduces CNS related effects, such as psychoactive effects.
Carlo Di Fonzo, Vice President of Drug Development and Regulatory Affairs at Nektar Therapeutics, will be presenting the latest research on NKTR-181 at Arrowhead 10th Annual Pain & Migraine Therapeutics Summit. His presentation will delve into the latest clinical applications of this drug, which focuses on evaluating its abuse potential in non-dependent, recreational opioid users. For more information on the 10th Annual Pain Summit, visit http://paintherapeuticsummit.com.
As an abuse-deterrent analgesic, NKTR-181 has the potential to eliminate the euphoria that can lead to opioid abuse/dependence, but also several other side-effects, such as respiratory distress and sedation. In preclinical trials, NKTR-181 has demonstrated: significantly reducing rate of entry into the CNS, equal analgesia to oxycodone, lower abuse liability, and reduced CNS side effects.
The 10th Annual Pain & Migraine Therapeutics Summit is the US’s premier pain conference covering the field of pain research and therapeutics. With various stakeholders in pharmaceutical, biotech, device and medical communities attending, this conference will provide multi-faceted perspectives on the latest pain research. For more information, please download a brochure at: www.paintherapeuticsummit.com/brochure.
For more information, please contact:
John Waslif: Managing Director
866-945-0263 ext 700
Rachel Donlon: Marketing Associate
866-945-0263 ext 701